Seventy percent of all breast cancers are ER+/PR+ and are treated with endocrine therapy that blocks ER activity with antiestrogens such as Tamoxifen or Faslodex/Fulvustrant/ICI or aromatase inhibitors such as letrozole [1,2]. Here, ESR1 is linked to breast cancer.